Results 191 to 200 of about 4,670,790 (255)

Advances in 3D Bioprinting for Breast Cancer Modeling: Tumor Microenvironment, Metastasis, and Drug Screening

Advanced Healthcare Materials, EarlyView.
Three‐dimensional bioprinting transforms breast cancer modeling from simple constructs into spatially organized, multicellular, perfused, and patient‐derived platforms. This review shows how bioinks, cellular composition, architecture, and flow govern tumor behavior and drug response, while revealing why complexity alone is insufficient without ...
Mustafa Nakipoglu, Mahboobeh Mahmoodi, Ehsanul Hoque Apu, Fahimeh Shahabipour, Sibel Emir Diltemiz, Sanjib Saha, Halima Alem, Nureddin Ashammakhi   +7 more
wiley   +1 more source

Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir Among Children Living with HIV Failing on First-Line Antiretroviral Therapy in Uganda. [PDF]

J Acquir Immune Defic Syndr
Magongo EN, Hast M, Nabitaka V, Nakanwagi M, Twinomujjuni E, Dowling S, Senyama G, Nzano B, Alwano M, Nakaweesi J, Nazziwa E, Namayanja G, Nkolo E, Ayitewala A, Hackett S.   +14 more
europepmc   +1 more source

Elastomeric 3D‐Printed Microenvironments Enable Nanonewton Force Measurements in Healthy and Diseased Human Pluripotent Stem Cell‐Derived Neuroepithelial Cells

Advanced Materials, EarlyView.
We present elastomeric three‐dimensional (3D) microstructures fabricated via two‐photon polymerization (2PP) and post‐processed through wet etching, for quantifying nanonewton (nN)‐scale forces applied by healthy and diseased neural cells. The mechanically characterized free‐standing beam architectures enable measurement of traction forces of ...
Pieter F. J. van Altena, Lucia Castillo Ransanz, Ruben H. Guis, Giulia Bergamaschi, Nanne J. Paauw, Urs Staufer, Vivi M. Heine, Angelo Accardo   +7 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Iterative Selection of DNA Nanostructures for Cellular Uptake

Advanced Materials, EarlyView.
DNA nanostructures are promising cell targeting delivery vehicles for therapeutics, but the targeting behavior is not fully understood. In this study, libraries of DNA nanostructures that can be amplified and sequenced are combined with cellular uptake as a selection pressure to iteratively refine DNA structures taken up in cells to better understand ...
Anjali Rajwar, Lisa Eichhorn, Jakub Palacka, Sandra Ly, Erik Benson   +4 more
wiley   +1 more source

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. [PDF]

Clin Infect Dis
Obeng BM, Hutchinson J, Shaik A, Chetchotisakd P, Azwa I, Wulan WN, Kumarasamy N, Wolff M, Bruguera J, Losso M, Kaplan R, Diallo MS, Eriobu N, Musoro G, Kumalawati J, Badamasi A, Fitriah M, Mulya DP, Law M, Matthews G, Di Giallonardo F, Kelleher AD, Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) Study Group.   +22 more
europepmc   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Next-Generation Sequencing Analysis for HIV-1 Genotyping and Drug Resistance Mutations Mapping in Sicily, Italy. [PDF]

Viruses
Pipitò L, Cannella S, Mascarella C, Graceffa D, Trizzino M, Iaria C, Colletti P, Mazzola G, Giammanco GM, Cascio A, Bonura C, Sicilian Grt Working Group.   +11 more
europepmc   +1 more source

Noncanonical HIV drug resistance mutations: need to close existing gaps. [PDF]

AIDS
Inzaule S, Jordan MR, Fokam J, Hamers RL, Paredes R, Crowell TA, Shafer RW, Schapiro J, Rinke de Wit TF, Charurat M, Kuritzkes DR, Ndembi N.   +11 more
europepmc   +1 more source

Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9‐CD36 Axis in Obesity‐Associated Pancreatic Adenocarcinoma

Advanced Science, EarlyView.
Pancreatic adenocarcinoma (PAAD) remains highly lethal with limited treatment options. This study demonstrates that coixenolide, a bioactive compound from Coix lacryma‐jobi L. and a key component of the clinically approved Kanglaite injection, exhibits enhanced antitumor efficacy in high‐fat diet (HFD)‐induced obese mice bearing PAAD tumors compared to
Kaidi Chen, Rong Chen, Wei Li, Bin Song, Ruiying Zhang, Lewei Dai, Yuwei Qi, Ruqian Chen, Yifan Xu, Hangbin Li, Jingyi Huang, Fangping Wu, Jianan Peng, Xinyu Wang, Yang Xiong, Chaofeng Mu, Guilin Cheng, Zhaoshen Li, Shanming Ruan, Lei Huang, Mancang Gu   +20 more
wiley   +1 more source